Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

Journal of Clinical Investigation

Volumn 108, Issue 5, 2001, Pages 669-678

  Cheng, Wen Fang ^a,b   Hung, Chien Fu ^a   Chai, Chee Yin ^a   Hsu, Keng Fu ^a   He, Liangmei ^a   Ling, Morris ^a   Wu, T C ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA;

ANGIOGENESIS; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; WART VIRUS;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CALCIUM-BINDING PROTEINS; CALRETICULIN; CANCER VACCINES; CELLS, CULTURED; DNA, NEOPLASM; ENDOPLASMIC RETICULUM; LUNG NEOPLASMS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS, VIRAL; RIBONUCLEOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0034788572     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200112346     Document Type: Article

References (54)

1. Tumor antigens recognized by T lymphocytes
2. Experimental vaccine strategies for cancer immunotherapy
3. Angiogenesis: Initiation and control
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Calreticulin: Not just another calcium-binding protein
6. Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation
7. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity
8. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin
9. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP
10. Angiogenesis in cancer, vascular, rheumatoid and other disease
11. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth
12. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
13. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen
14. Calreticulin: One protein, one gene, many functions
15. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand
16. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
17. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
18. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
19. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen
20. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments
21. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
22. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
23. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
24. HPV in situ hybridization with catalyzed signal amplification and polymerase chain reaction in establishing cerebellar metastasis of a cervical carcinoma
25. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma
26. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
27. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
28. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
29. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
30. Antigen processing in vivo and the elicitation of primary CTL responses
31. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope
32. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
33. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines
34. Heat shock proteins transfer peptides during antigen processing and CTL priming
35. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96
36. A mechanism for the specific immunogenicity of heat shock protein- chaperoned peptides
37. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
38. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
39. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
40. Cytokine networks in solid human tumors: Regulation of angiogenesis
41. The biology of chemokines and their receptors
42. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
43. Endostarin: An endogenous inhibitor of angiogenesis and tumor growth
44. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangionesis
45. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
46. Inhibition of angiogenesis in vivo by interleukin 12
47. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12
48. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
49. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
50. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
51. Potential DNA vaccine integration into host cell genome
52. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1
53. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
54. Pathophysiological roles of calreticulin in autoimmune disease